LLY
Eli Lilly and Company1054.29
-7.90-0.74%
Dec 16, 4:00:25 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Orforglipron launch details, access ramps
Q&A fleshed out orforglipron's launch playbook, eyeing market expansion from oral-curious patients and real-world satisfaction metrics, while clarifying ex-US rollouts mostly in 2027. International Mounjaro growth baselines off Q4 strength, now 75% out-of-pocket chronic weight. Medicare access kicks in by July with 10-20% LillyDirect bolus; employer opt-ins gain traction via dedicated teams. Orals expand the pie—no cannibalization fears. Pricing elasticity holds in cash channel. Management stayed crisp on access hurdles. Volume crushes price drags.
Key Stats
Market Cap
945.13BP/E (TTM)
51.55Basic EPS (TTM)
20.45Dividend Yield
0.01%Recent Filings
10-K
FY2025 results
Eli Lilly delivered FY2025 revenue of $65.2B, up 45% y/y, with U.S. sales surging 43% to $43.5B and ex-U.S. 48% to $21.7B, powered by Mounjaro and Zepbound which together drove 56% of total revenue amid robust volume gains offset by softer pricing. Gross margins expanded to 83.0% from 81.3%, fueling net income of $20.6B and diluted EPS of $22.95, both up ~95% y/y, despite R&D up 21% and MS&A up 29% on pipeline and launch investments. Q4 momentum shone through capex of $7.8B for capacity expansion and $4.1B in buybacks, with debt rising to $42.5B yet $10.1B in revolver capacity intact. No annual guidance disclosed in the 10-K. Compounding and counterfeit incretins threaten supply integrity.
8-K
Q4 revenue up 43%
Eli Lilly reported Q4 2025 revenue up 43% to $19.3 billion, fueled by Mounjaro and Zepbound volume surges, with EPS jumping 51% to $7.39 reported ($7.54 non-GAAP). Key wins included FDA nods for KwikPen tirzepatide and Jaypirca expansion, plus Phase 3 successes for Taltz-Zepbound combo and orforglipron. Revenue exploded. 2026 guidance targets $80-83 billion revenue, $33.50-35.00 non-GAAP EPS, but pricing pressures linger.
8-K
Lilly adds Bertozzi to board
Eli Lilly elected Carolyn R. Bertozzi, Ph.D., Stanford chemistry professor and Howard Hughes investigator, to its Board effective December 8, 2025. She joins the Science and Technology and Ethics committees, standing for shareholder vote in May 2026. Independent under NYSE rules. Bertozzi brings deep biotech expertise.
10-Q
Q3 FY2025 results
Eli Lilly crushed Q3 with revenue up 54% y/y to $17.6B, driven by Mounjaro and Zepbound exploding 109% and 185% respectively; gross margins climbed to 82.9% on mix shift, fueling net income to $5.6B and diluted EPS of $6.21 (up from $1.07, consistent with 899M shares). YTD revenue gained 46% to $45.9B, EPS $15.56. Cash swelled to $9.8B on $13.6B operating cash flow, despite $5.3B capex; total debt hit $42.5B after issuances, with $10B credit lines untapped. Verve deal closed July 2025 for $549M net cash, booking $608M IPR&D and $127M goodwill. Cash is king here.
8-K
Q3 revenue up 54%, guidance raised
Eli Lilly crushed Q3 with revenue surging 54% to $17.6 billion, powered by Mounjaro and Zepbound volume. EPS rocketed to $6.21 reported, $7.02 non-GAAP. Guidance leaped: full-year revenue $63.0-63.5 billion, non-GAAP EPS $23.00-23.70. Pipeline wins include orforglipron Phase 3 success and Inluriyo approval, but IPR&D charges hit $656 million.
IPO
Website
Employees
Sector
Industry
ABBV
AbbVie Inc.
223.67-3.78
AMGN
Amgen Inc.
326.74+1.43
AZN
Astrazeneca PLC
91.35-0.21
BIIB
Biogen Inc.
171.50-4.24
BMY
Bristol-Myers Squibb Company
54.23-0.06
JNJ
Johnson & Johnson
209.30-4.87
MRK
Merck & Company, Inc.
98.27-1.99
PFE
Pfizer, Inc.
25.53-0.90
TAK
Takeda Pharmaceutical Company L
14.53-0.08
VTRS
Viatris Inc.
11.46-0.20